Literature DB >> 23414327

Keratoacanthoma and other types of squamous cell carcinoma with crateriform architecture: classification and identification.

Noriyuki Misago1, Takuya Inoue, Shinichi Koba, Yutaka Narisawa.   

Abstract

The terminology and classification of keratoacanthoma (KA) and other types of squamous cell carcinoma (SCC) with crateriform architecture have not been clarified. The study evaluated the clinicopathological features of 41 nodular (exo-endophytic) SCC lesions with a central keratin-filled crater, including KA (well-developed stage). The lesions were histopathologically classified into six categories: (i) KA (well-developed stage) (27 lesions); (ii) KA-like SCC (three lesions); (iii) KA with malignant transformation (three lesions); (iv) infundibular SCC (crateriform) (four lesions); (v) crateriform SCC arisen from actinic keratosis (three lesions); and (vi) crateriform Bowen's disease (one lesion). The true characteristics of KA-like SCC remain unresolved, but there are three possibilities, namely, that it is one step in the evolution of KA, it is a borderline lesion between KA and invasive SCC, or it is one form of "KA with malignant transformation". KA, KA-like SCC, KA with malignant transformation and infundibular SCC (crater form) are considered to be hair follicle-related neoplasms. In contrast, crateriform SCC arisen from actinic keratosis and crateriform Bowen's disease are SCC, which are not related either to the hair follicles or KA. From an etiological standpoint, the presented lesions in these six categories are considered to be mixed up due to the similarity of crateriform architecture between the various types of lesions. However, the information provided in this report is intended to help physicians to make an accurate differential diagnosis of these conditions in clinical practice. The present study provides an opportunity to standardize the terminology for KA and related neoplasms.
© 2013 Japanese Dermatological Association.

Entities:  

Mesh:

Year:  2013        PMID: 23414327     DOI: 10.1111/1346-8138.12104

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  7 in total

Review 1.  [Actinic keratosis, Bowen's disease, keratoacanthoma and squamous cell carcinoma of the skin].

Authors:  M Majores; E Bierhoff
Journal:  Pathologe       Date:  2015-02       Impact factor: 1.011

Review 2.  Skin cancer - an overview for dentists.

Authors:  B J Steel
Journal:  Br Dent J       Date:  2014-05       Impact factor: 1.626

3.  Validation of an HPV16-mediated carcinogenesis mouse model.

Authors:  Katherine De Azambuja; Provabati Barman; Joy Toyama; David Elashoff; Gregory W Lawson; Lisa K Williams; Kristofer Chua; Deborah Lee; Joseph J Kehoe; Andre Brodkorb; Rebecca Schwiebert; Scott Kitchen; Aamir Bhimani; Dorothy J Wiley
Journal:  In Vivo       Date:  2014 Sep-Oct       Impact factor: 2.155

4.  Myriad facades of keratocanthoma: Benignity VS malignancy.

Authors:  Pooja Sharma; Anjali Narwal; Mala Kamboj
Journal:  J Oral Biol Craniofac Res       Date:  2019-09-19

5.  Keratoacanthoma versus invasive squamous cell carcinoma: a comparison of dermatoscopic vascular features in 510 cases.

Authors:  John H Pyne; Graham Windrum; Devendra Sapkota; Jian Cheng Wong
Journal:  Dermatol Pract Concept       Date:  2014-07-31

6.  Insulin-like growth factor 2 mRNA-binding protein-3 as a marker for distinguishing between cutaneous squamous cell carcinoma and keratoacanthoma.

Authors:  Akiko Kanzaki; Mitsuhiro Kudo; Shin-Ichi Ansai; Wei-Xia Peng; Kousuke Ishino; Tetsushi Yamamoto; Ryuichi Wada; Takenori Fujii; Kiyoshi Teduka; Kiyoko Kawahara; Yoko Kawamoto; Taeko Kitamura; Seiji Kawana; Hidehisa Saeki; Zenya Naito
Journal:  Int J Oncol       Date:  2016-01-05       Impact factor: 5.650

7.  Cytokeratin 17 and Ki-67: Immunohistochemical markers for the differential diagnosis of keratoacanthoma and squamous cell carcinoma.

Authors:  Cem Leblebici; Esra Pasaoglu; Canan Kelten; Seher Darakci; Nevra Dursun
Journal:  Oncol Lett       Date:  2017-03-01       Impact factor: 2.967

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.